Councellors

Councellors 2018-01-22T18:24:45+00:00

Councellors

Dr. Armando Gabrielli

1975-1978:  Instructor, Istituto di Patologia Medica e Metodologia Clinica, University of Ancona

1977: Assistant Resident, Istituto di Patologia Medica e Metodologia Clinica, University of Ancona

1982:  Visiting Professor – Dpt. of Laboratory Medicine, University of  South Carolina, Charleston, USA

  • Lecturer, School of Specialization in Haematology

1984-1989: Lecturer, School of Specialization in Immunohaematology

1984-1992:  Lecturer, School of Specialization in Internal Medicine

1985-1985: Visiting Scientist- Max Planck Institute fur Biochemie, Munchen

1985-1985: Fellowship of the European Molecular Biology Organization

1988-1988: Visiting Scientist- Max Planck Institute fur Biochemie, Munchen

1992-2000: Associate Professor in Internal Medicine, Istituto di Clinica Medica Generale, Ematologia ed   Immunologia Clinica, University of Ancona, Italy

1996:  Director of Laboratory of Molecular Medicine, Istituto di Clinica Medica Generale, Ematologia ed Immunologia Clinica University of Ancona, Italy

2000: Full Professor of Internal Medicine, Istituto di Clinica Medica Generale, Ematologia ed Immunologia Clinica Università Politecnica delle Marche, Italy.

2004: President, Fondazione di Medicina Molecolare e Cellulare, Ancona, Italy

2005: Chairman Division of Clinica Medica, Ospedali Riuniti, Ancona, Italy

2013: Chairman Full Professor of Internal Medicine, Dipartimento di Scienze Cliniche e Molecolari, Clinica Medica, Università Politecnica delle Marche, Italy.

2013: Head of the Division of the Laboratory of Clinical Immunology

2016: Member of the Scientific Board of EUSTAR (EULAR Scleroderma Trials and Research)

Luchetti MM, Paroncini P, Majlingova P, Frampton J, Mucenski M, Svegliati Baroni S, Sambo P, Introna M, Gabrielli A. Characterization of the c-myb responsive region of the human type I collagen a2 chain gene. J Biol Chem 278, 1533-41, 2003

Clements PJ, Becvar R, Drosos AA, Ghattas L, Gabrielli A. Assessment of gastrointestinal involvement in scleroderma.  Clin Exp Rheumatol 21 (S) 15-18, 2003

Luchetti MM, Sambo P, Mjilingova P, Svegliati Baroni S, Paroncini P, Peri G, Introna M, Stoppacciaro A, Mantovani A, Gabrielli A. Scleroderma fibroblasts constitutively express the long pentraxin PTX3. Clin Exp Rheumatol  22, 66-72, 2004

Del Rosso A, Cinelli M, Guiducci S, Pignone A, Fibbi G, Margheri F, Gabrielli A, Giacomelli R, Coppini A, Del Rosso M, Matucci Cerinic M. Deflazacort modulates the fibrinolytic pattern and reduces uPA-dependent chemioinvasion and proliferation in rheumatoid arthritis synoviocytes.. Rheumatology 44:1255-62, 2005

Monti G, Pioltelli P, Saccardo F, Campanini M, Candela M, Cavallero G, De Vita S, Ferri C, Mazzaro C, Migliaresi S, Ossi E, Pietrogrande M, Gabrielli A, Galli M, Invernizzi F. Incidence and characteristics of Non-Hodgkin lymphomas in a multicenter case file of patients with hepatitis c virus-related symptomatic mixed cryoglobulinemia. Arch Intern Med 165, 101-105, 2005

Nesci S, Iliescu A, Buffi O, Sista T,  Luchetti M, Gabrielli A, Rinaldi G. A novel HLA-Cw*6 allele, Cw*160102, identified by clonino and sequencing. Tisse Antigens 65: 580-1 2005

Caggiari L, Simula MP, Marzotto A, Caragnano A, Luchetti M, Gabrielli A, De Re V Identification of a novel human DRB1*13 allele by sequence-based DRB typing Tissue Antigens  66:246-7. 2005

Bandinelli F, Bartoli F,Perfetto F, Del Rosso A, Pignone A, Guiducci S, Fatini C, Generini S, Gabrielli A, Giacomelli A,  Maddali Bongi S, Abbate R, Del Rosso M, Matucci Cerinic M The fibrinolytic system components are increased in Systemic Sclerosis and modulated by Alprostadil (alpha1 ciclodestryn). Clin Exp Rheumatol. 23: 671-7 2005

Guiducci S, Del Rosso A, Cinelli M, Perfetto F, Livi R, Rossi A, Gabrielli A, Giacomelli R, Iori N,  Fibbi G, Del Rosso M, Matucci Cerinic M. Raloxifene reduces urokinase-type plasminogen activator-dependent proliferation of synoviocytes from patients with rheumatoid arthritis Arthritis Res Ther 7, 1244-1253, 2005.

Dziadzio M, Anastassiades CP, Hawkins PN, Potter M, Gabrielli A, Brough GM, Black CM, Denton CP. From scleredema to AL amyloidosis: disease progression or coincidence? Review of the literature. Clin Rheumatol 25; 3-15, 2005

Svegliati Baroni S, Cancello R, Sambo P, Luchetti M, Paroncini P, Orlandini G,  Discepoli G, Paterno’ R, Santillo MR, Cozzo I, Silvana Cassano, Avvedimento EV, Gabrielli A Platelet-derived growth factor and reactive oxygen species (ROS) regulate Ras protein levels in primary human fibroblasts via ERK 1-2. Amplification of ROS-ERK-Ras signalling in scleroderma fibroblasts. J Biol Chem 280; 36474-82, 2005

Moroncini G,  Mangieri M ,  Morbin M,  Mazzoleni G, Ghetti B, Gabrielli A, Williamson RA, Giaccone G,   Tagliavini F  Pathologic prion protein is specifically recognized in situ by a novel PrP conformational antibody. Neurobiology Dis 23; 7171-724,2006

Svegliati Baroni S, Santillo MR Bevilacqua F, Luchetti M, Spadoni T, Mancini M , Fraticelli P, Sambo P, Funaro A , Kazlauskas A, Avvedimento EV, Gabrielli A Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis . N Engl J Med 354; 2667-76, 2006

Gabrielli A Svegliati Baroni S, Avvedimento EV, Stimulatory autoantibodies to the PDGF receptor in scleroderma (Correspondence). N Engl J Med 354; 1279, 2006

Del Papa N, Quirici N, Soligo D, Cortina M, Scavullo C, Borsotti C, Maglione W, Comina DP, Vitali C, Fraticelli P, Gabrielli A, Cortelezzi A, Lambertenghi-Deliliers G Bone marrow endothelial progenitors are defective in systemic sclerosis Arthritis Rheum 54; 2605-15, 2006

Cinelli M, Guiducci S; Del Rosso A; Pignone A; Del Rosso M; Fibbi G; Serratì S; Gabrielli A; Giacomelli R; Piccardi N, Matucci Cerinic, M Piascledine modullates the production of VEGF and TIMP-1 and reduces the invasiveness of rheumatoid arthritis syniviocytes  Scan J Rheumatol 2006, 35:346-50.

Ferrera F, Rizzi M, Sprecacenere B, Balestra P, Sessarego M, Di Carlo A, Filaci G, Gabrielli A Ravazzolo R Indiveri F AIRE gene polymorphisms in Systemic Sclerosis associated with Autoimmune Thyroiditis Clin Immunol 122; 13-7, 2007

Svegliati S, Olivieri A, Campelli N, Luchetti M, Poloni A, Trappolini S, Moroncini  G, Bacigalupo A, Leoni P, Avvedimento EV,  Gabrielli A.  Stimulatory aotoantibodies to the PDGF receptor in patients with estensive chronic graft-versus-host disease, Blood 110: 237-241,2007

 

Kopecki Z, Luchetti M, Adams D, Strudwick X, Mantamadiotis T, Stoppacciaro A, Gabrielli A, Ramsay R, Cowin A Collagen loss and impaired woud healing is associated with c- Myb deficiency J Pathol 211; 351- 61, 2007

Danieli MG, Calcabrini L, Marchetti AL, Calabrese V, Pettinari L, Massaccesi C, Gabrielli A, Danieli G La terapia con immunoglobuline endovena nelle malattie autoimmuni. Rec Prog Med 98: 322-326, 2007

De Re V, Caggiari L, Simula MP, De Vita S, Mazzero C, Lenzi M, Galli M, Monti G, Ferri C, Zignego AL, Gabrielli A, Sansonno D, Dammacco F, Libra M, Sacchi N, Salamini R, Spina M, Tirelli U, Cannizzaro R, Dolcetti R. Role of HLA Class II in HCV-related disorders Ann N Y Acad Sci 1107: 308-318, 2007

Gabrielli A, Svegliati S, Moroncini G, M. Luchetti, C. Tonnini, Avvedimento EV. Stimulatory Autoantibodies to the PDGF receptor: a link to fibrosis and a pathway for novel therapeutic targets  Autoimmunity Rev 7; 121-126, 2007

Gabrielli A, Svegliati A, Moroncini G, Avvedimento EV Pathogenic autoantibodies in systemic sclerosis. Curr Opin Immunol 19, 640-645, 2007

Denton CP, Pope JE, Peter HH, Gabrielli A, Boonstra A, van den Hoogen F, Riemkasten G, De Vita S, Morganti A, Berkani O, Guillevin L. Long-term effects of Bosentan on quality of life, survival, safety and tolerability in pulmonary arterial hypertension related to connective tissue diseases. Ann Rheum Dis 67; 1222-28, 2008

Gabrielli A, Svegliati S, Moroncini G, Pomponio G, Santillo M, Avvedimento   EV Oxidative stress and the pathogenesis of scleroderma: the Murrell’s hypothesis revisited. Sem Immunopathol 30; 329-37, 2008

 

Walker UA, Tyndall A, Czirják L, Denton C, Farge-Bancel D, Kowal-Bielecka O, Müller-Ladner U, Matucci-Cerinic M, Gabrielli A and EUSTAR Co-authors  Geographic variation of disease manifestations in systemic sclerosis – a report from the EULAR Scleroderma Trials And Research (EUSTAR) group data base. Ann Rheum Dis 68; 856-62, 2009

Distler HWJ, Allanore Y, Avouac J, Giacomelli R, Guiducci S, Moritz F, Akhmetshina A, Walzer U, Gabrielli A, Muller-Landner U, Tyndal A, Matucci-Cerinic M, Distler O. EUSTAR statement and recommendations on endothelial precursor cells in systemic sclerosis. Ann Rheum Dis 68, 163-168, 2009

Krieg T, Hunzelmann N, Gabrielli A, Jablonska S. Scleroderma. Eur J Dermatol. 2008; 18(2):213-4.

Gabrielli A, Avvedimento EV, Krieg T. Scleroderma.  N Engl J Med 360: 1989-2003, 2009

Danieli MG, Calcabrini L, Calabrese V, Marchetti A, Logullo F, Gabrielli A. Intravenous immunoglobulins add on treatment with mycophenolate mofetil in severe myositis. Autoimmunity Rev  9: 124-7, 2009

Danieli MG, Marchetti A, Monteforte F, Calabrese V, Pettinari L, Gabrielli A. Splenic microcalcifications in systemic lupus erythematosus. Lupus 18: 570-1, 2009

 

 

Martucci F, Acutis P, Mazza M, Nodari S, Colussi S, Corona C, Barocci S, Gabrielli A, Caramelli M, Casalone C, Moroncini G. Detection of typical and atypical bovine spongiform encephalopathy and scrapie prion strains by prion protein motif-grafted antibodies. J Gen Virol. 90:1048-53, 2009

 

Giuliodori G, Fraticelli P, bartolini M, Cagnetti C, Baruffaldi R, Rocchi MBL, Provinciali L, Gabrielli A, Silvestrini M. Cognitive and cerebral hemodynamic impairment in scleroderma patients. Eur J Neur 16:1285-90, 2009

Olivieri A, Locatelli F, Zecca M, Sanna A, Cimminiello M, Raimondi R, Gini G, Mordini N, Balduzzi A, Leoni P, Gabrielli A, Bacigalupo A. Imatinib for refractory chronic Graft-versus-Host disease with fibrotic features. Blood 114: 700-718, 2009;

Gabrielli A, Moroncini G, Avvedimento EV. Autoantibodies against PDGF receptor in scleroderma (correspondence) Arthritis Rheum  60; 3521-3522, 2009

Avvedimento EV, Gabrielli A Stiff and tight skin: a rear window into fibrosis without inflammation. Science Transl Med. 2010 Mar 17;2(23):23ps13.

Avouac J, Walker U, Tyndall A, Gabrielli A et al Characteristics of joint involvement and relationships with systemic inflammation in systemic sclerosis: results from the EULAR Scleroderma Trial and Research Group (EUSTAR) database. J Rheumatol. 37:1488-501, 2010

Bocchino ML, Agnese S, Fagone E, Svegliati S, Grieco D, Vancheri C, Gabrielli A, Sanduzzi A, Avvedimento EV. Involvement of reactive oxygen species in the phenotypic characterization of primary lung fibroblasts from idiopathic pulmonary fibrosis patients PLoS One 2010; 5: e14003

 

Avouac J, Fransen J, Walker UA, Riccieri V, Smith V, Muller C, Miniati I, Tarner IH, Randone SB, Cutolo M, Allanore Y, Distler O, Valentini G, Czirjak L, Muller-Ladner U, Furst DE, Tyndall A, Matucci-Cerinic M, Gabrielli A. EUSTAR Group Preliminary criteria for the very, early diagnosis of systemic sclerosis: results of a Delphi consensus study from EULAR scleroderma trials and research group. Ann Rheum Dis 70; 476-81 2011

 

Smaldone S, Olivieri J, Gusella L, Moroncini G, Gabrielli A Ramirez F. Ha-Ras stabilization mediates pro-fibrotic signals in dermal fibroblasts Fibrogenesis & Tissue Repair 2011, 4:8.

 

Herrick AL, van den Hoogen F, Gabrielli A, Tamimi N, Reid C, O’Connell D, Vazquez-Abad MD, Denton CP. Modified-release sildenafil reduces Raynaud’s attack frequency in limited cutaneous systemic sclerosis. Arthritis Rheum 63; 775-782, 2011

 

Pietrogrande M, DeVita S, Zignego A, Gabrielli A et al. Recommendations for the management of mixed cryoglobulinemia syndrome in epatitis C virus- infected patients. Autoimmunity Rev 10;  444-454, 2011

Danieli MG, Pettinari L, Moretti R, LoGullo F, Gabrielli A Subcutaneous immunoglobulins in polymyositis and dermatomyositis: a novel application. Autoimmunity Rev  10; 144-149, 2011

Fransen J, Popa-Diaconu D, Hesselstrand R, Carreira P, Valentini G, Berena L, Airo P, Inanc M, Ullman S, Balbir-Gurman A, Sierakowski S, Allanore Y, Czirjak L, Riccieri V, Giacomelli R, Gabrielli A, Riemekasten G, Matucci-Cerinic M, Farge D, Hunzelmann N, Van den Hoogen FHJ, Vonk MC  Clinical prediction of 5-year survival in systemic sclerosis: validation of a simple prognostic model in EUSTAR centres Ann Rheum Dis 70; 1788-1792, 2011

De Vita S, Soldano F, Isola M, Monti G, Gabrielli A, Tzioufas A, Ferri C, Ferraccioli GF, Quartuccio L, Corazza L, De Marchi G, Casals MR, Voulgarelis M, Lenzi M, Saccardo F, Fraticelli P, Mascia MT, Sansonno D, Cacoub P, Tomsic M, Tavoni A, Pietrogrande M, Zignego AL, Scarpato S, Mazzaro C, Pioltelli P, Steinfeld S, Lamprecht P, Bombardieri S, Galli M Preliminary classification criteria for the cryoglobulinemic vasculitis. Ann Rheum Dis 70; 1183-1190, 2011

 

Fransen J, Johnson SR, van den Hoogen F, Baron M, Allanore Y, Denton C, Furst D Carreira P, Czirjak L, Distler O, , Gabrielli A, Herrick A, Inanc M, Kahaleh B, Kowal-Bielecka O, Medsger T, Mueller-Ladner U, Riemekasten G, Sierakowski S, Valentini G, Veale D, Vonk M, Chung L, Clements P, Collier D, Csuka ME, Jimenez S, Merkel P, Seibold J, Silver R, Steen V, Tyndall A, Matucci-Cerinic M, Pope JE, Khanna D. Items for developing revised classification criteria in systemic sclerosis: results of a consensus exercise. Arthritis Care & Res 2012; 64: 351-357;

De Vita S, Quartuccio L, Isola M, Mazzaro C, Scaini P, Lenzi M, Campanini M, Naclerio C,Tavoni A, Pietrogrande M, Ferri C, Mascia MT, Masolini P, Zabotti A, Maset M, Roccatello D, Zignego AL, Pioltelli P, Gabrielli A, Filippini D, Perrella O, Migliaresi S, Galli M, Bombardieri S, Monti G. A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. Arthritis Rheum. 2012 64: 843-53.

Bartoloni E, Alunno A, Bistoni O, Bizzaro N, Migliorini P, Morozzi G, Doria A, Mathieu A, Lotzinker M, Allegri F, Riccieri V, Alpini C, Gabrielli A,  Tamponio  M, Gerli  R Diagnostic value of anti-mutated citrullinated vimentin in comparison to anti- cyclic citrullinated peptide and anti-viral citrullinated peptide 2 antibodies in rheumatoid arthritis: an Italian multicentric study and review of the literature. Autoimmunity Rev 11; 815-820, 2012

Quartuccio L, Isola M, Corazza L, Maset M, Monti G, Gabrielli A, Tzioufas A, Ferri C, Ferraccioli G, Ramos-Casals M, Voulgarelis M, Lenzi M, Mascia MT, Sansonno D, Cacoub P, Tomsic M, Tavoni A, Pietrogrande M, Zignego AL, Scarpato S, Pioltelli P, Steinfeld S, Lamprecht P, Bombardieri S, Galli M, De Vita S. Performance of the preliminary classification criteria for cryoglobulinaemic vasculitis and clinical manifestations in hepatitis C virus-unrelated cryoglobulinaemic vasculitis. Clin Exp Rheumatol 30; 48-52, 2012

 

Gabrielli A, Svegliati S, Moroncini G, Amico D New Insights into the role of oxidative stress in scleroderma fibrosis Open J Rheumatol  6; 87-95, 2012

Bandinelli F, Del Rosso A, Gabrielli A, Giacomelli R, Bartoli F, Guiducci S, Matucci Cerinic M.  CCL2, CCL3 and CCL5 chemokines in systemic sclerosis the correlation with SSc clinical features and the effect of prostaglandin E1 treatment. Clin Exp Rheumatol 30; S44-9, 2012

Denton CP, Krieg T, Guillevin L, Schwierin B, Rosenberg D, Silkey M, Zultak M, Matucci-Cerinic M; DUO Registry investigators Demographic, clinical and antibody characteristics of patients with digital ulcers in systemic sclerosis: data from the DUO Registry. Ann Rheum Dis. 71(5):718-21, 2012

Menditto VG, Lucci M, Polonara S, Pomponio G, Gabrielli A. Management of minor head injury in patients receiving oral anticoagulant therapy: a prospective study of a 24-hour observation protocol. Ann Emerg Med. 59:451-5, 2012

Bonifazi M, Tramacere I, Pomponio G, Gabrielli B, Avvedimento  EV, La Vecchia C, Negri E, Gabrielli A. Scleroderma and cancer risk: systematic review and meta-analysis of observational studies” Rheumatology  52, 143-54, 2013

Orciani M, , Svegliati S, Gorbi S, Spadoni T, Lazzarini R, Regoli F, Di Primio R, Gabrielli A  Alterations of ROS pathway in scleroderma begin at stem cell level. J Biol Reg Homeost. Agents 27, 211-24, 2013

 

van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, Matucci-Cerinic M, Naden R, Medsger TA Jr, Carreira P, Riemekasten G, Clements P, Denton C, Distler O, Allanore Y, Furst DE, Gabrielli A, Mayes M, van Laar J, Seibold JR, Czirjak L, Steen V, Inanc M, Kowl-Bielecka O, Müller-Ladner U, Valentini G, Veale D, Vonk M, Walker U, Chung L, Collier D, Csuka ME, Fessler BJ, Guiducci S, Herrick A, Hsu V, Jimenez S, Kahaleh B, Merkel P, Sierakowski S, Silver R, Simms R, J Varga J, Pope JE.  2013 Classification Criteria for Systemic Sclerosis: An American College of Rheumatology/European League against rheumatism Collaborative Initiative Arthritis Rheum 65, 2737-47, 2013

Campanati A, Moroncini G, Ganzetti  G, Pozniak KN, Goteri G, Giuliano A, Martina E,  Liberati G, Gabrielli A, Offidani A  Adalimumab modulates angiogenesis in psoriatic skin.  Eur J Inflamm 1, 489-498, 2013

Moroncini G, Mori S, Tonnini C, Gabrielli A. Role of viral infections in the etiopathogenesis of systemic sclerosis. Clin Exp Rheumatol 31, 3-7, 2013

 

Cuccioloni M, Moroncini G, Mozzicafreddo M, Pozniak KN, Nacci G, Grieco A, Paolini C, Tonnini C, Funaro A, Angeletti A, Gabrielli A. Biosensor-based Binding Assay for Platelet-Derived Growth Factor Receptor-α Autoantibodies in Human Serum J Anal Bioanal Tech S7: 010; 2013

van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, Matucci-Cerinic M, Naden R, Medsger TA Jr, Carreira P, Riemekasten G, Clements P, Denton C, Distler O, Allanore Y, Furst DE, Gabrielli A, Mayes M, van Laar J, Seibold JR, Czirjak L, Steen V, Inanc M, Kowl-Bielecka O, Müller-Ladner U, Valentini G, Veale D, Vonk M, Walker U, Chung L, Collier D, Csuka ME, Fessler BJ, Guiducci S, Herrick A, Hsu V, Jimenez S, Kahaleh B, Merkel P, Sierakowski S, Silver R, Simms R, J Varga J, Pope JE.  2013 Classification Criteria for Systemic Sclerosis: An American College of Rheumatology/European League against rheumatism Collaborative Initiative. Ann Rheum Dis 72:1747-55, 2013

Olivieri A, Cimminiello MMC, Corradini P, Mordini N, Fedele R, Selleri C, Onida F, Patriarca F, Pavone E, Svegliati S, Gabrielli A, Bresciani P, Nuccorini R, Pascale S, Coluzzi S, Pane F, Poloni A, Olivieri J, Pane F, Leoni P, Bacigalupo A Long term outcome and prospective validation of NIH response criteria in 39 patients receiving Imatinib for steroid-refractory chronic GVHD. Blood 122, 4111-8, 2013

 

Fattal I, Shental N, Molad Y, Gabrielli A, Pokroy-Shapira E, Oren S,  Livneh A, Langevitz P, Pauzner R, Sarig O, Gafter U, Domany E, Cohen IR.  Epstein-Barr virus antibodies mark systemic lupus erythematosus and scleroderma patients negative for anti-DNA. Immunology. 141, 276-85. 2014

 

Danieli MG, Moretti R, Gambini S, Paolini L, Gabrielli A Open-label study on treatment with 20% subcutaneous IgG administration in Polymyositis and Dermatomyositis. Clin Rheumatol 33,  531-6, 2014

 

Danieli MG, Gelardi C, Pedini V, Moretti R, Gabrielli A, Logullo F. Subcutaneous IgG in immune-mediate diseases: proposed mechanisms of action and literature review. Autoimmun Rev 13,1182-8, 2014

 

Moroncini G, Pomponio G, Dziadzio M, Paci della Costanza O, Alessandra Pierfederici A, Ferretti L, Giuseppe Pupita G, Luca Salvolini L, Andrea Giovagnoni A, Gabrielli A Myocardial perfusion defects in scleroderma detected by contrast-enhanced cardiovascular magnetic resonance. La Radiologia Medica 119, 885-94, 2014

 

 

Donati A, Damiani E, Luchetti MM, Domizi R, Scorcella C, Carsetti A, Gabbanelli V, Carletti P, Bencivenga R, Vink H, Adrario E, Piagnerelli M,  Gabrielli A, Pelaia P, Ince C.  Microcirculatory effects of the transfusion of leukodepleted or non-leukodepleted red blood cells in septic patients: a pilot study. Crit Care 18, R33, 2014

 

Maurer B, Graf N, Michel BA, Müller-Ladner U, László Czirják, Denton C, Tyndall A, Baron M, Metzig C, Lanius V, Khanna D, Distler O   Gabrielli A and EUSTAR co-authors Prediction of worsening of skin fibrosis in patients with diffuse cutaneous systemic sclerosis using the EUSTAR database. Ann Rheum Dis 74, 1124-31, 2015

 

Johnson SR, Naden RP, Fransen J, van den Hoogen F, Pope JE, Baron M, Tyndall A, Matucci-Cerinic M, Denton CP, Distler O, Gabrielli A, van Laar J, Mayes M, Steen V, Seibold JR, Clements P, Medsger TAJr17, Carreira PE, Riemekasten G, Chung L,. Fessler BJ, Merkel P, Silver R, Varga J, Allanore Y, Mueller-Ladner U, Vonk MC, Walker UA, Cappelli S, Khanna D. Multicriteria decision analysis methods with 1000Minds for developing systemic sclerosis classification criteria J Clin Epidemiol 67, 706-14, 2014

Quartuccio L, Isola M, Corazza L, Ramos-Casals M, Retamozo S, Ragab GM, Zoheir MN, El-Menyawi MA, Salem MN, Sansonno D, Ferraccioli G, Gremese E, Tzioufas A, Voulgarelis M, Vassilopoulos D, Scarpato S, Pipitone N, Salvarani C, Guillevin L, Terrier B, Cacoub P, Filippini D, Saccardo F, Gabrielli A, Fraticelli P, Sebastiani M, Tomsic M, Tavoni A, Mazzaro C, Pioltelli P, Nishimoto N, Scaini P, Zignego AL, Ferri C, Monti G, Pietrogrande M, Bombardieri S, Galli M, De Vita S. Validation of the classification criteria for cryoglobulinaemic vasculitis.Rheumatology (Oxford). 53, 2209-13, 2014

EULAR Textbook on Systemic Sclerosis Ed Eric Hachulla, L Czirjak BMJ Autoantibodies, autoimmunity Masataka Kuwana, Armando Gabrielli pp 88-96, 2014

 

Svegliati S, Marrone G, Pezone A, Spadoni T, Grieco A, Moroncini G, Grieco D, Vinciguerra M, Agnese S, Jungel A, Distler O., Musti AM, Gabrielli A, Avvedimento EV. Oxidative DNA damage induces the ATM-mediated transcriptional suppression of the WNT inhibitor WIF-1 in systemic sclerosis and fibrosis. Science Signal 7,ra84, 2014

 Nobili L. Albani L, Gabrielli A, Moroncini G.  Reactivation of hepatitis B virus infection associated with anti- tumor necrosis factor –a therapy. J Antivir Antiretrovir 6, 3, 2014

Danieli MG, Gambini S, Pettinari L Logullo F, Veronesi G, Gabrielli A. Impact of treatment on survival in polymyositis and dermatomyositis. A single-Centre long term follow-up study. Autoimmunity Rev 13, 1048-54, 2014

Fraticelli P, Gabrielli B, Pomponio G, Valentini G, Bosello S, Riboldi P, Gerosa M, Faggioli P, Giacomelli R, Del Papa N, Gerli R, Lunardi C, Bombardieri S, Malorni W,  Corvetta A, Moroncini G,  Gabrielli A  on behalf of “Imatinib in Scleroderma Italian Study Group” Low-dose Oral Imatinib in the Treatment of Systemic Sclerosis Interstitial Lung Disease unresponsive to cyclophosphamide. A Phase II Pilot Study. Arthritis Res Therapy 16:R144, 2014

Lonati PA, Brembilla NC, Montanari  E, Fontao L, Gabrielli A, Vettori S, Valentini G, Laffitte E; Kaya G, Meroni PL, Chizzolini C High IL-17E and low IL-17C dermal expression identifies a fibrosis-specific motif common to morphea and systemic sclerosis”. PLoS one 9, e105008, 2014

 

Fattal I, Rimer J, Shental N, Molad Y, Gabrielli A, Livneh A, Sarig O, Goldberg I, Gafter U, Domany E, Cohen IR.  Pemphigus vulgaris is characterized by low IgG reactivities to specific self-antigens along with high IgG reactivity to desmoglein 3. Immunology 143:374-80, 2014

 

Del Papa N, Di Luca G, Sambataro D, Zaccara E, Maglione W, Gabrielli A, Fraticelli P, Moroncini G, Beretta L, Santaniello A, Sambataro G, Ferraresi R, Vitali C. Reply to J. Magalon et al. Cell Transplant  24, 2669-70, 2015

Moroncini G, Grieco A, Nacci G, Paolini C, Tonnini C, Katarzyna N. Pozniak1, Cuccioloni M, Mozzicafreddo M, Silvia Svegliati S, Angeletti M, Kazlauskas A, Avvedimento EV, Funaro A, Gabrielli A. Epitope specificity determines pathogenicity and detectability of anti-PDGFRa autoantibodies in systemic sclerosis  Arthritis Rheumatol 67; 1891–1903; 2015

Jordan S, Distler JHW, Maurer B, Huscher D, van Laar JM, Allanore Y, Distler O, , Gabrielli A EUSTAR rituximab study group. Effects and safety of Rituximab (RTX) in Systemic sclerosis: an analysis from the European Scleroderma Trial and Research group (EUSTAR). Ann Rheum Dis 74, 1188-94, 2015

 

Fattal I, Shental N, Ben-Dor S, Molad Y, Gabrielli A, Pokroy-Shapira E, Oren S, Livneh A, Langevitz P, Zandman-Goddard G, Sarig O, Margalit R, Gafter U, Domany E, Cohen IR. Guanine polynucleotides are self-antigens for human natural autoantibodies and are significantly reduced in the human genome. Immunology 146:401-10, 2015

 

 

Bonifazi M, Francesca Bravi F,  Gasparini S, La Vecchia C, Gabrielli A, Wells A, Renzoni E Sarcoidosis and cancer risk: systematic review and meta-analysis of observational studies. Chest 147, 778-91,2015

 

Damiani E, Adrario  E, Luchetti MM, Scorcella C, Carsetti A, Mininno N, Pierantozzi S, Principi T, Strovegli D, Bencivenga R, Gabrielli A, Romano R, Pelaia P, Ince C, Donati A. Plasma free haemoglobin and microcirculatory response to fresh or old red blood transfusions in sepsis. PLoS One 10, e0122655, 2015

 

Donzelli G, Carnesecchi G, Amador C, di Tommaso M, Filippi L, Caporali R, Codullo V, Riccieri V, Valesini G, Gabrielli A, Bagnati R, McGreevy KS, De Masi S, Matucci Cerinic M Fetal programming and systemic sclerosis. Am J Obstet Gynecol 213: 839.e1-8, 2015

Del Papa N, Di Luca G, Sambataro D, Zaccaro E, Maglione W, Gabrielli A, Fraticelli P, Moroncini G, Beretta L, Santaniello A, Sambataro G, Vitali C. Regional implantation of autologous adipose tissue-derived cells induces a prompt healing of long-lasting indolent digital ulcers in patients with Systemic sclerosis Cell transplant 24, 2297-305, 2015

Tedesco S, Postacchini L, Manfredi L, Goteri G, Luchetti MM, Festa A, Gabrielli A, Pomponio G Successful treatment of a Caucasian case of multifocal Castleman’s disease with TAFRO Syndrome with a pathophysiology targeted therapy. A case report. Experimental Hematology & Oncology 4:3, 2015

Iudici M, Moroncini G, Cipriani P, Giacomelli R, Gabrielli A, Valentini G Where are we going in the management of interstitial lung disease in patients with systemic sclerosis? Autoimmun Rev. 14, 575-578, 2015

 

Fraticelli P, De Vita S, Franzolini N, Svegliati S, Scott C, Tonnini C, Spadoni T, Gabrielli B, Pomponio G, Moroncini G, Gabrielli A Reduced type I collagen gene expression by skin fibroblasts of patients with systemic sclerosis after one treatment course with rituximab. Clin Exp Rheumatol 33, 160-167, 2015

 

Spadoni T, Svegliati Baroni S, Amico D, Albani L, Moroncini G, Avvedimento EV, Gabrielli A. A reactive oxygen species-mediated loop maintains the increased expression of NADPH oxidases 2 and 4 in skin fibroblasts from patients with systemic sclerosis. Arthritis Rheumatol 67, 1611–1622, 2015

Amico D, Spadoni T, Rovinelli M, Serafini M, D’Amico G, Campelli N, Svegliati S, Gabrielli A. Intracellular free radical production by peripheral blood T lymphocytes from patients with Systemic Sclerosis: role of NADPH oxidase and ERK1/2. Arthritis Res Therapy 17, 68, 2015

Olivieri J, Manfredi L, Postacchini L, Tedesco S, Leoni P, Gabrielli A, Rambaldi A, Bacigalupo A, Olivieri A, Pomponio G. Consensus recommendations for improvement of unmet clinical needs? The example of chronic graft-versus-host disease: a systematic review and meta-analysis. Lancet Haematol 2, e297-305, 2015

Quartuccio L. et al Quartuccio L, Zuliani F, Corazza L, Scaini P, Zani R, Lenzi M, Tavoni A, Sebastiani M, Baldovino S, Urraro T, Saccardo F, Sbreglia C, Mazzaro C, Pioltelli P, Fraticelli P, Filippini D, Gabrielli A, Perrella O, Scarpato S, Roccatello D, Zignego AL, Ferri C, Bombardieri S, Pietrogrande M, Monti G, Galli M, De Vita S. Retreatment regimen of rituximab monotherapy given at the relapse of severe HCV-related cryoglobulinemic vasculitis: Long term follow up of a randomized controlled multicenter study J of Autoimmunity 63, 88-93, 2015

Luchetti MM , Moroncini G, Escamez MJ, Svegliati Baroni S, Spadoni T, Grieco A, Paolini C, Avvedimento EV, Larcher F, Del Rio M, Gabrielli A Induction of scleroderma fibrosis in skin-humanized mice by administration of anti-Platelet-Derived Growth Factor receptor agonistic autoantibodies. Arthritis Rheumatol 68, 2263-73, 2016

 

Luchetti MM, Balloni A, Gabrielli A. Biologic Therapy in Inflammatory and Immunomediated Arthritis: Safety Profile.Curr Drug Saf. 11:22-34, 2016

Iudici M, Moroncini G, Cipriani P, Giacomelli R, Gabrielli A, Valentini G. Comment on ‘Where are we going in the management of interstitial lung disease in patients with systemic sclerosis?’. Autoimmun Rev 15: 202, 2016

Brembilla NC, Dufour AM, Alvarez M, Hugues S, Montanari E, Truchetet ME, Lonati P, Fontao L, Gabrielli A, Vettori S, Valentini G, Boehncke WH, Meroni P, Chizzolini C.  IL-22 capacitates dermal fibroblast responses to TNF in scleroderma. Ann Rheum Dis. 75:1697-705; 2016

Danieli MG, Gelardi C, Guerra F, Cardinaletti P, Pedini V, Gabrielli A. Cardiac involvement in polymyositis and dermatomyositis. Autoimmun Rev 15, 462-5, 2016.

López-Isac E, Campillo-Davo D, Bossini-Castillo L, Guerra SG, Assassi S, Simeón CP, Carreira P, Ortego-Centeno N, García de la Peña P; Spanish Scleroderma Group, Beretta L, Santaniello A, Bellocchi C, Lunardi C, Moroncini G, Gabrielli A, Riemekasten G, Witte T, Hunzelmann N, Kreuter A, Distler JH, Voskuyl AE, de Vries-Bouwstra J, Herrick A, Worthington J, Denton CP, Fonseca C, Radstake TR, Mayes MD, Martín J Influence of TYK2 in Systemic Sclerosis susceptibility: a new locus in the IL-12 pathway” Ann Rheum Dis  75, 1521-6, 2016

López-Isac E, Martín JE, Assassi S, Simeón CP, Carreira P, Ortego-Centeno N, Freire M, Beltrán E, Narváez J, Alegre-Sancho JJ; Spanish Scleroderma Group, Fernández-Gutiérrez B, Balsa A, Ortiz AM, González-Gay MA, Beretta L, Santaniello A, Bellocchi C, Lunardi C, Moroncini G, Gabrielli A, Witte T, Hunzelmann N, Distler JH, Riekemasten G, van der Helm-van Mil AH, de Vries-Bouwstra J, Magro-Checa C, Voskuyl AE, Vonk MC, Molberg Ø, Merriman T, Hesselstrand R, Nordin A, Padyukov L, Herrick A, Eyre S, Koeleman BP, Denton CP, Fonseca C, Radstake TR, Worthington J, Mayes MD, Martín J. Brief report: IRF4 newly identified as a common susceptibility locus for Systemic Sclerosis and Rheumatoid Arthritis in a cross-disease meta-analysis of Genome-wide Association Studies. Arthritis Rheumatol 68, 2338-44,2016

 Fraticelli P, Kafyeke A, Mattioli M, Martino GP, Murri M, Gabrielli A. Idiopathic hypereosinophilic syndrome presenting with severe vasculitis successfully treated with Imatinib. World Journal of Clin Cases In Press

Fraticelli P, Bagnarelli P, Tarantino G, Martino GP, Benfaremo D, Nobili L , Mandolesi A, Barbisan F, Marinelli K, Mattioli M, Murri, M, Gabrielli A Chronic hepatitis E in a patient treated with rituximab and mycophenolate mofetil for Sjogren’s syndrome Rheumatology In Press

Bianchi T, Wolcott RD, Peghetti A, Leaper D, Cutting K, Polignano R, Rosa Rita Z, Moscatelli A, Greco A, Romanelli M, Pancani S, Bellingeri A, Ruggeri V, Postacchini S, Tedesco S, Manfredi L, Camerlingo M, Rowan S,Gabrielli A Pomponio G, Recommendations for the management of biofilm: a consensus document Journal of Wound Care  25, 305-17, 2016

 

Moroncini G, Albani L, Nobili L, Gabrielli A. Biologic Therapy in Inflammatory Immunomediated Systemic Diseases: Safety Profile. Curr Drug Saf 11: 44-6, 2016

Salaffi F, Fraticelli P, Carotti M, Fischetti C, Di Carlo M, Giuseppetti GM, Gabrielli A. Internal and external responsiveness of computer-aided quantification of interstitial lung disease from high resolution computed tomogrophy images in Systemmic sclerosis: comparison with visual reader-based score. Sarcoidosis vasculitis and diffuse lung disease In Press

Ciccia F, Guggino  G, Rizzo, Alessandro R, Luchetti MM, Milling S, Saieva L, Cypers H, Stampone T, Gabrielli A, Fasano A, Elewaut D, Triolo G. Dysbiosis and Zonulin up-regulation alter gut epithelial and vascular barriers in patients with Ankylosing Spondylitis. Annals Rheum Dis In Press

Svegliati S, Amico D, Spadoni T, Fischetti C, Finke D, Moroncini G, Paolini C, Tonnini C, Grieco A, Rovinelli M, Gabrielli A. Agonistic anti-PDGF receptor autoantibodies from patients with Systemic sclerosis impact human pulmonary artery smooth mucle cells in vitro. Front Immunol In Press

Prof. Alexandra Balbir Gurman

Prof. Alexandra Balbir-Gurman, MD has been Director of the B. Shine Rheumatology Institute at Rambam Health Care Campus since 2007. She immigrated to Israel from Ukraine in 1989 and completed her Residency in Internal Medicine (1990-1994) in the Department of Internal Medicine at B’nai Zion Hospital; she specialized in Rheumatology Department at Rambam (1994-1997) and has been a Senior Rheumatologist since 1997. In 2000, she had a fellowship in The Connective Tissue Diseases Unit at Royal Free Hospital in London under Prof. Carol M. Black. Prof. Balbir-Gurman is Clinical Associate Professor at the Technion Faculty of Medicine; she is also a member of national (Israeli Society of Rheumatology) and international organizations, such as ACR and EULAR; she is an active member and counsellor of the Scleroderma Research Group (EUSTAR) and a member of the EULAR Target US initiative. Prof. Balbir-Gurman has organized several US courses for Israeli rheumatologists, workshops on vascular problems in Scleroderma and capillaroscopy; every two years she organizes an International Rheumatology Conference on the Scientific Basis of Rheumatology in Israel. Prof. Balbir-Gurman maintains the largest Israeli scleroderma registry, and operates a busy scleroderma clinic and a multidisciplinary fibro-vascular clinic for patients with respiratory problems and rheumatic diseases. She has published articles in the field of scleroderma, myositis, vasculitis, rheumatoid arthritis, biological therapies, and the use of US in rheumatic diseases.

Dr. Nikolas Hunzelmann

Dr. Nicolas Hunzelmann is deputy director of the Department of Dermatology at the University of Cologne. He is cofounder of the German Network of systemic scleroderma in 2002 and currently head of the network. He started his residency in rheumatology with Prof. Kalden in Erlangen followed by a research postdoctoral training at the LMU Munich and the MPI for Biochemistry in Munich before switching to dermatology and receiving board certification in dermatology and allergology. Starting with his research training he has been working on basic aspects of extracellular matrix synthesis and turnover in the skin and extending his interests to diagnosis and therapy of autoimmune skin diseases with a particular emphasis on systemic sclerosis. With a strong link to clinical studies he initiated the registry of the German network of SSc, which currently has included more than 4000 patients  containing information both on clinical data and therapy.

Pr. Duska Martinoivc

Dušanka Martinović Kaliterna is Head of Division of rheumatology and Clinical immunology, University of Split, School of Medicine. She is Full Professor of Internal medicine, rheumatology and immunology. She is born in Split, Dalmatia where she finished her primary schools, the Medical study she have done in 1978. at Belgrade University. She did the Master Studies and PhD from University of Zagreb, School of Medicine. Her main interest and field of scientific work is immune endocrinology, antiphospholipid syndrome and systemic sclerosis and she created the PHD thesis of her students in this area. For many years she has been active in organization of international scientific meeting and educational curses of this field in Croatia and partly in Europe. She was involved in national ethic committees and ethic commit of Medical school, University of Split. She initiated and supported patient’s organizations for Systemic lupus and Scleroderma in Dalmatia and Croatia. She is awarded by Croatian Medical Association with high award “Ladislav Rakovac” for her contribution in medical science in Croatia. She is author and coauthor in 9 books and more than 100 internationally indexed papers.